Stocktoria
Coherus Oncology, Inc. CHRS
Coherus Oncology, Inc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $42.2M | $26.4M | $257.2M | $211.0M | $326.6M | $475.8M | $356.1M | $0 | $1.6M | $190.1M |
| R&D expense | $108.9M | $91.8M | $109.4M | $199.4M | $363.1M | $142.8M | $94.2M | $110.2M | $162.4M | $254.4M |
| SG&A expense | $100.6M | $125.5M | $192.0M | $198.5M | $169.7M | $139.1M | $137.0M | $94.2M | $71.3M | $51.6M |
| Operating income | -$181.1M | -$199.7M | -$203.2M | -$256.9M | -$263.9M | $156.3M | $107.8M | -$204.4M | -$232.1M | -$115.9M |
| Interest expense | $9.0M | $10.7M | $40.5M | $32.5M | $23.0M | $21.2M | $17.6M | $9.7M | $9.6M | $8.0M |
| Income tax | $0 | $0 | -$380,000 | $0 | $0 | $3.5M | $2.9M | $0 | $0 | $0 |
| Net income | $168.0M | $28.5M | -$237.9M | -$291.8M | -$287.1M | $132.2M | $89.8M | -$209.3M | -$238.2M | -$127.3M |
| EPS (diluted) | $1.43 | $0.25 | $-2.53 | $-3.76 | $-3.81 | $1.62 | $1.23 | $-3.22 | $-4.48 | — |
| Operating cash flow | -$138.5M | -$20.4M | -$174.9M | -$241.1M | -$37.4M | $154.1M | $28.4M | -$159.3M | -$200.3M | -$252.5M |
| Free cash flow | — | — | -$175.2M | -$243.2M | -$38.7M | $146.9M | $26.5M | -$160.1M | -$204.9M | -$259.1M |
| Cash & equivalents | $88.9M | $126.0M | $102.9M | $63.5M | $417.2M | $541.2M | $177.7M | $72.4M | $126.9M | $124.9M |
| Inventory | $3.2M | $4.2M | $62.6M | $38.8M | $37.6M | $44.2M | $9.8M | $1.7M | — | — |
| Total assets | $258.3M | $448.5M | $629.6M | $480.8M | $679.3M | $841.6M | $408.9M | $99.5M | $162.6M | $178.5M |
| Total liabilities | $197.3M | $580.5M | $823.0M | $618.3M | $581.6M | $560.7M | $303.7M | $138.1M | $132.1M | $159.1M |
| Shareholders' equity | $61.0M | -$132.0M | -$193.4M | -$137.4M | $97.7M | $281.0M | $105.2M | -$38.6M | $30.5M | $20.5M |
Growth · year-over-year · Revenue CAGR -15.4%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +59.8% | -89.7% | +21.9% | -35.4% | -31.4% | +33.6% | — | -100.0% | -99.2% | +532.8% |
| Net income growth | +489.4% | — | — | — | -317.1% | +47.2% | — | — | — | — |
| EPS growth | +472.0% | — | — | — | -335.2% | +31.7% | — | — | — | — |
| Free cash flow growth | — | — | — | — | -126.4% | +453.7% | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.